Typical Vs Atypical Hemolytic Uremic Syndrome _best_ Jun 2026

Atypical HUS, in contrast, is a rare but devastating disease that can affect individuals of any age, from infancy to adulthood. Its name, "atypical," belies its clinical gravity. Unlike typical HUS, aHUS is not preceded by STEC infection. Instead, it is a primary disease of uncontrolled complement activation. In the majority of cases, aHUS is caused by inherited genetic mutations in complement regulatory proteins (e.g., factor H, factor I, MCP) or in activating proteins (e.g., factor B, C3). These mutations lead to a state of chronic, unchecked activation of the alternative complement pathway, resulting in persistent attack on the endothelium.

In healthy individuals, regulatory proteins (like Factor H, Factor I, or MCP) keep the complement system in check. In aHUS, mutations in these regulatory genes mean the immune system attacks the body's own endothelial cells. This leads to the same outcome as Typical HUS—microvascular clotting and cell destruction—but the "trigger" is internal, not external. typical vs atypical hemolytic uremic syndrome

Atypical HUS (aHUS) represents a completely different beast. Historically, any HUS not associated with Shiga toxin was labeled "atypical," but advances in genetics have refined this definition. aHUS is now understood as a disease of . Atypical HUS, in contrast, is a rare but

Clinically, typical HUS presents with a classic prodrome of several days of watery diarrhea followed by bloody diarrhea (dysentery). Approximately five to ten days after the onset of diarrhea, the triad of HUS manifests: pallor (anemia), petechiae and bruising (thrombocytopenia), and decreased urine output (acute kidney injury). The prognosis for typical HUS is surprisingly favorable. With aggressive supportive care—including meticulous fluid and electrolyte management, blood transfusions, and often dialysis—the majority of children recover renal function completely. The mortality rate is low (1-5%) in the acute phase, and long-term sequelae, such as chronic kidney disease or hypertension, occur in a minority of patients. Crucially, typical HUS is not a recurrent disease; once a patient recovers from the acute infection, the syndrome does not return. Instead, it is a primary disease of uncontrolled

In summary, while typical and atypical HUS share a common histopathological appearance and clinical triad, they are fundamentally distinct entities. Typical HUS is an acute, self-limited, toxin-mediated condition triggered by a gastrointestinal infection, primarily affecting children and carrying a good prognosis with supportive care. Atypical HUS is a chronic, genetic disease of complement dysregulation, affecting all ages, characterized by a high risk of recurrence and progression to ESRD. The distinction is not merely academic; it is the pivot upon which accurate diagnosis, appropriate treatment (supportive care versus complement inhibition), and accurate prognosis hinge. For the clinician, suspecting HUS is only the first step; the crucial second step is to determine which face of the syndrome is staring back.